Track: CME Session
Jose Karam, MD, FACS
University of Texas MD Anderson Cancer Center
University of Texas MD Anderson Cancer Center
Disclosure information not submitted.
Mehmet Bilen, MD
Winship Cancer Institute of Emory University
Disclosure(s): Advisory board: Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi (Ongoing)
Contract Research: Amgen, Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer (Ongoing)
Mamta Parikh, MD, MS
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
Disclosure information not submitted.
Sarah Psutka, MD MS
University of Washington
University of Washington
Seattle, Washington, United States
Disclosure information not submitted.
Rahul Sheth, MD
University of Texas MD Anderson Cancer Center
Disclosure(s): Non-CE Consulting: Boston Scientific (Ongoing); Replimune (Ongoing); Siemens (Ongoing); TriSalus Life Sciences (Ongoing)
Eric Singer, MD, MA, MS, FACS, FASCO
The Ohio State University Comprehensive Cancer Center
The Ohio State University Comprehensive Cancer Center
Columbus, OH, United States
Disclosure(s): No financial relationships to disclose
Moderator: Jose A. Karam, MD, FACS – University of Texas MD Anderson Cancer Center
Panelist: Mehmet A. Bilen, MD – Winship Cancer Institute of Emory University
Panelist: Mamta Parikh, MD, MS – UC Davis Comprehensive Cancer Center
Panelist: Sarah Psutka, MD MS – University of Washington
Panelist: Rahul Sheth, MD – University of Texas MD Anderson Cancer Center
Panelist: Eric A. Singer, MD, MA, MS, FACS, FASCO – The Ohio State University Comprehensive Cancer Center